139 related articles for article (PubMed ID: 8811119)
1. Metabolites of 5-fluorouracil, alpha-fluoro-beta-alanine and fluoroacetic acid, directly injure myelinated fibers in tissue culture.
Akiba T; Okeda R; Tajima T
Acta Neuropathol; 1996 Jul; 92(1):8-13. PubMed ID: 8811119
[TBL] [Abstract][Full Text] [Related]
2. Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compounds in dogs.
Okeda R; Karakama T; Kimura S; Toizumi S; Mitsushima T; Yokoyama Y
Acta Neuropathol; 1984; 63(4):334-43. PubMed ID: 6433643
[TBL] [Abstract][Full Text] [Related]
3. Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs.
Yamashita K; Yada H; Ariyoshi T
J Toxicol Sci; 2004 May; 29(2):155-66. PubMed ID: 15206584
[TBL] [Abstract][Full Text] [Related]
4. Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine.
Okeda R; Shibutani M; Matsuo T; Kuroiwa T; Shimokawa R; Tajima T
Acta Neuropathol; 1990; 81(1):66-73. PubMed ID: 2128162
[TBL] [Abstract][Full Text] [Related]
5. Subacute neurotoxicity of 5-fluorouracil and its derivative, carmofur, in cats.
Okeda R; Shibutani M; Matsuo T; Kuroiwa T
Acta Pathol Jpn; 1988 Oct; 38(10):1255-66. PubMed ID: 3218507
[TBL] [Abstract][Full Text] [Related]
6. Excretion of 1-hexylcarbamoyl-5-fluorouracil in urine of mice.
Iigo M; Nakamura A; Kuretani K; Hoshi A
J Pharmacobiodyn; 1981 Jul; 4(7):490-6. PubMed ID: 6795334
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Kuwata K; Nagayama S; Hirakawa Y; Matsushima E; Kawaguchi Y
Gan To Kagaku Ryoho; 2000 Jun; 27(6):885-90. PubMed ID: 10897216
[TBL] [Abstract][Full Text] [Related]
8. Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.
Fischel JL; Formento P; Ciccolini J; Etienne-Grimaldi MC; Milano G
Anticancer Drugs; 2004 Nov; 15(10):969-74. PubMed ID: 15514566
[TBL] [Abstract][Full Text] [Related]
9. In vivo 19F NMR comparative study of 5-fluorouracil, 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) and an FT-uracil coadministration system in mouse tumors.
Kanazawa Y; Kurogi S; Shinohara S; Noda Y; Masuda K
Chem Pharm Bull (Tokyo); 1994 Apr; 42(4):774-8. PubMed ID: 8020119
[TBL] [Abstract][Full Text] [Related]
10. Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.
Baehring JM; Fulbright RK
J Neurol Neurosurg Psychiatry; 2008 May; 79(5):535-9. PubMed ID: 17682013
[TBL] [Abstract][Full Text] [Related]
11. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M
Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250
[TBL] [Abstract][Full Text] [Related]
12. 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.
Muneoka K; Shirai Y; Yokoyama N; Wakai T; Hatakeyama K
Int J Clin Oncol; 2005 Dec; 10(6):441-3. PubMed ID: 16369751
[TBL] [Abstract][Full Text] [Related]
13. The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells.
Reis-Mendes A; Carvalho F; Remião F; Sousa E; Bastos ML; Costa VM
Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30862114
[TBL] [Abstract][Full Text] [Related]
14. Formation of conjugates of 2-fluoro-beta-alanine and bile acids during the metabolism of 5-fluorouracil and 5-fluoro-2-deoxyuridine in the isolated perfused rat liver.
Sweeny DJ; Barnes S; Diasio RB
Cancer Res; 1988 Apr; 48(8):2010-4. PubMed ID: 2964897
[TBL] [Abstract][Full Text] [Related]
15. Fluoropyrimidine chemotherapy in a rat model: comparison of fluorouracil metabolite profiles determined by high-field 19F-NMR spectroscopy of tissues ex vivo with therapy response and toxicity for locoregional vs systemic infusion protocols.
Lutz NW; Naser-Hijazi B; Koroma S; Berger MR; Hull WE
NMR Biomed; 2004 May; 17(3):101-31. PubMed ID: 15137037
[TBL] [Abstract][Full Text] [Related]
16. Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed compound of tegafur and uracil), carmofur and 5'-deoxy-5-fluorouridine.
Ooi A; Ohkubo T; Higashigawa M; Kawasaki H; Kakito H; Kagawa Y; Kojima M; Sakurai M
Biol Pharm Bull; 2001 Nov; 24(11):1329-31. PubMed ID: 11725974
[TBL] [Abstract][Full Text] [Related]
17. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.
Hull WE; Port RE; Herrmann R; Britsch B; Kunz W
Cancer Res; 1988 Mar; 48(6):1680-8. PubMed ID: 3125967
[TBL] [Abstract][Full Text] [Related]
18. Development of a sensitive and selective LC-MS/MS method for the determination of alpha-fluoro-beta-alanine, 5-fluorouracil and capecitabine in human plasma.
Licea-Perez H; Wang S; Bowen C
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Apr; 877(11-12):1040-6. PubMed ID: 19285927
[TBL] [Abstract][Full Text] [Related]
19. A mathematical model of the kinetics and tissue distribution of 2-fluoro-beta-alanine, the major catabolite of 5-fluorouracil.
Zhang R; Liu T; Soong SJ; Diasio RB
Biochem Pharmacol; 1993 May; 45(10):2063-9. PubMed ID: 8512588
[TBL] [Abstract][Full Text] [Related]
20. [An oral repeated dose toxicity study of a new antineoplastic agent S-1 in dogs. I. A 13-week repeated dose toxicity study. II. An ophthalmologic toxicity recovery study].
Hayashi T; Yamaguchi S; Kito S; Tanaka G; Kurokawa K; Hirota T
J Toxicol Sci; 1996 Nov; 21 Suppl 3():527-44. PubMed ID: 9021660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
